RNN - Rexahn Pharmaceuticals, Inc.

NYSE American - NYSE American Delayed price. Currency in USD
+0.12 (+7.50%)
At close: 4:00PM EDT

1.72 0.00 (0.00%)
After hours: 4:19PM EDT

Stock chart is not supported by your current browser
Previous close1.60
Bid1.72 x 200
Ask1.73 x 500
Day's range1.59 - 1.76
52-week range0.39 - 4.74
Avg. volume250,369
Market cap54.6M
PE ratio (TTM)N/A
EPS (TTM)-0.92
Earnings date26 Feb 2018 - 2 Mar 2018
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est12.83
Trade prices are not sourced from all markets
  • Globe Newswire3 months ago

    Rexahn Pharmaceuticals Receives Notice of Allowance for A New U.S. Patent Covering the Use of RX-5902 (Supinoxin™)

    Rexahn Pharmaceuticals, Inc. (NYSE American:RNN), a clinical stage biopharmaceutical company developing innovative, targeted therapeutics for the treatment of cancer, today announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for U.S. Patent Application No. 15/255,901, “Quinoxalinyl Piperazinamide Methods of Use”.  The allowed patent application covers the use of RX-5902, also known as Supinoxin for the treatment of cancers including triple negative breast cancer either as monotherapy or in combination with other anti-tumor agents such as cytotoxic agents or immune checkpoint inhibitors.

  • Associated Press6 months ago

    Rexahn reports 3Q loss

    The Rockville, Maryland-based company said it had a loss of 4 cents per share. Losses, adjusted for non-recurring gains, came to 15 cents per share. The results topped Wall Street expectations. The average ...

  • Rexahn Pharmaceuticals (RNN) in Focus: Stock Moves 6.1% Higher
    Zacks6 months ago

    Rexahn Pharmaceuticals (RNN) in Focus: Stock Moves 6.1% Higher

    Rexahn Pharmaceuticals (RNN) was a big mover last session, as the company saw its shares rise more than 6% on the day.

By using Yahoo you agree that Yahoo and partners may use Cookies for personalisation and other purposes